New antibody drug takes aim at Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC